Lepu Biopharma Doubles Revenue, Advances Pipeline

Lepu Biopharma Co. Ltd. Class H (HK:2157) has released an update.

Lepu Biopharma Co., Ltd. has reported a strong first half of 2024 with a revenue of RMB94.8 million from PUYOUHENG (Pucotenlimab Injection) sales, doubling the previous year’s figures. Significant progress has been made in advancing the company’s ADC pipeline and combination therapies, with positive clinical trial results and presentations at major medical conferences planned. The company also showcased promising pre-clinical data for new candidates developed from its innovative platforms, with one candidate, MRG006A, moving into Phase I clinical studies.

For further insights into HK:2157 stock, check out TipRanks’ Stock Analysis page.